Originally published as JCO Early Release 10.1200/JCO.2005.05.546 on June 6 2005
Journal of Clinical Oncology, Vol 23, No 22 (August 1), 2005: pp. 4856-4865
© 2005 American Society of Clinical Oncology.
Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986
C.-H. Köhne,
E. van Cutsem,
J. Wils,
C. Bokemeyer,
M. El-Serafi,
M.P. Lutz,
M. Lorenz,
P. Reichardt,
H. Rückle-Lanz,
N. Frickhofen,
R. Fuchs,
H.-G. Mergenthaler,
T. Langenbuch,
U. Vanhoefer,
P. Rougier,
R. Voigtmann,
L. Müller,
B. Genicot,
Ö. Anak,
B. Nordlinger
From the Department of Internal Medicine, University of Dresden, Dresden; Universitätsklinik Tübingen, Tübingen; Medizinische Klinik, Saarbrücken; Charite Virchow Klinikum, Berlin; Medizinische Poliklinik der Universität, Würzburg; Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden; St Antonius-Hospital, Eschweiler; Katharinhospital, Stuttgart; Kreiskrankenhaus, Aurich; University of Essen, Essen; Marienenhospital Ruhr University, Herne; Onkologische Schwerpunkpraxis, Leer, Germany; University Hospital, Gasthuisberg, Leuven; European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium; Laurentius Ziekenhuis, Roermond, the Netherlands; National Cancer Institute, Cairo, Egypt; and Hopital Ambroise Paré, Boulogne, France
Deceased.
Address reprint requests to Claus-Henning Köhne, MD, Klinikum Oldenburg, Klinik für Oncology/Hematology, Dr.-Edenstr. 10, 26133 Oldenburg, Germany; e-mail: onkologie{at}klinikum-oldenburg.de
PURPOSE: To demonstrate that adding irinotecan to a standard weekly schedule of high-dose, infusional fluorouracil (FU) and leucovorin (folinic acid [FA]) can prolong progression-free survival (PFS).
PATIENTS AND METHODS: Four hundred thirty patients with measurable or assessable metastatic colorectal cancer were randomly assigned to receive either FA 500 mg/m2 as a 2-hour infusion and FU 2.6 g/m2 by intravenous 24-hour infusion, both administered weekly for 6 weeks, followed by a 2-week rest (Arbeitsgemeinschaft für Internistische Onkologie [AIO] arm, n = 216), or a similar schedule but with FU 2.3 or 2.0 g/m2 preceded by irinotecan 80 mg/m2 administered over 30 minutes (experimental group, n = 214).
RESULTS: The median PFS time in the experimental group was 8.5 months (95% CI, 7.6 to 9.9 months) compared with 6.4 months (95% CI, 5.3 to 7.2 months) in the AIO arm (P < .0001). The median overall survival time was increased from 16.9 to 20.1 months (P = .2779). The objective response rate was 62.2% (95% CI, 55.0% to 69.5%) in the experimental group and 34.4% (95% CI, 27.5% to 41.3%) in the AIO arm (P < .0001).
CONCLUSION: The addition of irinotecan to the standard AIO FU/FA regimen was associated with a highly significant improvement in PFS and response rate and was well tolerated. The results of this study confirm that irinotecan in combination with high-dose infusional FU/FA is a reference first-line treatment.
Supported by an educational grant from Aventis Pharma, Antony, France.
Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003.
Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
Related Editorial
- Whither Irinotecan?
Charles D. Blanke
JCO 2005 23: 4811-4814
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
A. Grothey and D. J. Sargent
Reply to F. Montagnani et al
J. Clin. Oncol.,
October 1, 2009;
27(28):
e134 - e135.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Grothey
Review: Medical treatment of advanced colorectal cancer in 2009
Therapeutic Advances in Medical Oncology,
September 1, 2009;
1(2):
55 - 68.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. KIM, S. A. ROH, D. H. CHO, T. W. KIM, S. N. YOON, C. W. KIM, C. S. YU, S. Y. KIM, and Y. S. KIM
Chemoresponsiveness Associated with Canonical Molecular Changes in Colorectal Adenocarcinomas
Anticancer Res,
August 1, 2009;
29(8):
3115 - 3123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Van Cutsem, R. Labianca, G. Bodoky, C. Barone, E. Aranda, B. Nordlinger, C. Topham, J. Tabernero, T. Andre, A. F. Sobrero, et al.
Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
J. Clin. Oncol.,
July 1, 2009;
27(19):
3117 - 3125.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Sargent, C. H. Kohne, H. K. Sanoff, B. M. Bot, M. T. Seymour, A. de Gramont, R. Porschen, L. B. Saltz, P. Rougier, C. Tournigand, et al.
Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer
J. Clin. Oncol.,
April 20, 2009;
27(12):
1948 - 1955.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Pencreach, E. Guerin, C. Nicolet, I. Lelong-Rebel, A.-C. Voegeli, P. Oudet, A. K. Larsen, M.-P. Gaub, and D. Guenot
Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1{alpha} Axis
Clin. Cancer Res.,
February 15, 2009;
15(4):
1297 - 1307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Aranda, M. Valladares, M. Martinez-Villacampa, M. Benavides, A. Gomez, B. Massutti, E. Marcuello, M. Constenla, J. C. Camara, A. Carrato, et al.
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study
Ann. Onc.,
February 1, 2009;
20(2):
251 - 257.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. BIR, A. A. FORA, C. LEVEA, and M. G. FAKIH
Spontaneous Regression of Colorectal Cancer Metastatic to Retroperitoneal Lymph Nodes
Anticancer Res,
February 1, 2009;
29(2):
465 - 468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, and M. Aapro
Treatment of the elderly colorectal cancer patient: SIOG expert recommendations
Ann. Onc.,
January 1, 2009;
20(1):
5 - 16.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Machida, T. Yoshino, N. Boku, S. Hironaka, Y. Onozawa, A. Fukutomi, K. Yamazaki, H. Yasui, K. Taku, and M. Asaka
Impact of Baseline Sum of Longest Diameter in Target Lesions by RECIST on Survival of Patients with Metastatic Colorectal Cancer
Jpn. J. Clin. Oncol.,
October 1, 2008;
38(10):
689 - 694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Alberts and L. D. Wagman
Chemotherapy for Colorectal Cancer Liver Metastases
Oncologist,
October 1, 2008;
13(10):
1063 - 1073.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Adam, R. J. de Haas, D. A. Wicherts, T. A. Aloia, V. Delvart, D. Azoulay, H. Bismuth, and D. Castaing
Is Hepatic Resection Justified After Chemotherapy in Patients With Colorectal Liver Metastases and Lymph Node Involvement?
J. Clin. Oncol.,
August 1, 2008;
26(22):
3672 - 3680.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Arnold, T. Hohler, C. Dittrich, F. Lordick, T. Seufferlein, J. Riemann, E. Woll, T. Herrmann, A. Zubel, and H.-J. Schmoll
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group
Ann. Onc.,
August 1, 2008;
19(8):
1442 - 1449.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-H. Kohne, J. De Greve, J. T. Hartmann, I. Lang, P. Vergauwe, K. Becker, D. Braumann, E. Joosens, L. Muller, J. Janssens, et al.
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015
Ann. Onc.,
May 1, 2008;
19(5):
920 - 926.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-H. Kohne, G. Folprecht, R. M. Goldberg, E. Mitry, and P. Rougier
Chemotherapy in Elderly Patients with Colorectal Cancer
Oncologist,
April 1, 2008;
13(4):
390 - 402.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Folprecht, M. T. Seymour, L. Saltz, J.-Y. Douillard, H. Hecker, R. J. Stephens, T. S. Maughan, E. Van Cutsem, P. Rougier, E. Mitry, et al.
Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials
J. Clin. Oncol.,
March 20, 2008;
26(9):
1443 - 1451.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Grothey, E. E. Hedrick, R. D. Mass, S. Sarkar, S. Suzuki, R. K. Ramanathan, H. I. Hurwitz, R. M. Goldberg, and D. J. Sargent
Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
J. Clin. Oncol.,
January 10, 2008;
26(2):
183 - 189.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Folprecht, J. Tabernero, C.-H. Kohne, C. Zacharchuk, L. Paz-Ares, F. Rojo, S. Quinn, E. Casado, R. Salazar, R. Abbas, et al.
Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer
Clin. Cancer Res.,
January 1, 2008;
14(1):
215 - 223.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Pawlik, R. D. Schulick, and M. A. Choti
Expanding Criteria for Resectability of Colorectal Liver Metastases
Oncologist,
January 1, 2008;
13(1):
51 - 64.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Tabernero, E. Van Cutsem, E. Diaz-Rubio, A. Cervantes, Y. Humblet, T. Andre, J.-L. Van Laethem, P. Soulie, E. Casado, C. Verslype, et al.
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer
J. Clin. Oncol.,
November 20, 2007;
25(33):
5225 - 5232.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Tang, S. M. Bentzen, E. X. Chen, and L. L. Siu
Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy
J. Clin. Oncol.,
October 10, 2007;
25(29):
4562 - 4568.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yoshino, N. Boku, Y. Onozawa, S. Hironaka, A. Fukutomi, Y. Yamaguchi, N. Hasuike, K. Yamazaki, N. Machida, and H. Ono
Efficacy and Safety of an Irinotecan plus Bolus 5-Fluorouracil and L-Leucovorin Regimen for Metastatic Colorectal Cancer in Japanese Patients: Experience in a Single Institution in Japan
Jpn. J. Clin. Oncol.,
September 1, 2007;
37(9):
686 - 691.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Zhang, O. A. Press, C. A. Haiman, D. Y. Yang, M. A. Gordon, W. Fazzone, A. El-khoueiry, S. Iqbal, A. E. Sherrod, G. Lurje, et al.
Association of Methylenetetrahydrofolate Reductase Gene Polymorphisms and Sex-Specific Survival in Patients With Metastatic Colon Cancer
J. Clin. Oncol.,
August 20, 2007;
25(24):
3726 - 3731.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. J. Meropol
A Renewed Call for Equipoise
J. Clin. Oncol.,
August 10, 2007;
25(23):
3392 - 3394.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Hiraoka, T. Kimura, C. R. Logg, C.-K. Tai, K. Haga, G. W. Lawson, and N. Kasahara
Therapeutic Efficacy of Replication-Competent Retrovirus Vector-Mediated Suicide Gene Therapy in a Multifocal Colorectal Cancer Metastasis Model
Cancer Res.,
June 1, 2007;
67(11):
5345 - 5353.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. K. Sanoff, H. Bleiberg, and R. M. Goldberg
Managing Older Patients With Colorectal Cancer
J. Clin. Oncol.,
May 10, 2007;
25(14):
1891 - 1897.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, C. Barbara, L. Crino, G. Benedetti, W. Evangelista, L. Fanchini, et al.
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
J. Clin. Oncol.,
May 1, 2007;
25(13):
1670 - 1676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Goldberg, M. L. Rothenberg, E. Van Cutsem, A. B. Benson III, C. D. Blanke, R. B. Diasio, A. Grothey, H.-J. Lenz, N. J. Meropol, R. K. Ramanathan, et al.
The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer
Oncologist,
January 1, 2007;
12(1):
38 - 50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Benoist, A. Brouquet, C. Penna, C. Julie, M. El Hajjam, S. Chagnon, E. Mitry, P. Rougier, and B. Nordlinger
Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure?
J. Clin. Oncol.,
August 20, 2006;
24(24):
3939 - 3945.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Masi, L. Marcucci, F. Loupakis, E. Cerri, C. Barbara, S. Bursi, G. Allegrini, I. M. Brunetti, R. Murr, S. Ricci, et al.
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer
Ann. Onc.,
August 1, 2006;
17(8):
1249 - 1254.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Goto, Y. Yamada, H. Yasui, K. Kato, T. Hamaguchi, K. Muro, Y. Shimada, and K. Shirao
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer
Ann. Onc.,
June 1, 2006;
17(6):
968 - 973.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Innocenti, E. E. Vokes, and M. J. Ratain
Irinogenetics: What Is the Right Star?
J. Clin. Oncol.,
May 20, 2006;
24(15):
2221 - 2224.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Folprecht, M. P. Lutz, P. Schoffski, T. Seufferlein, A. Nolting, P. Pollert, and C.-H. Kohne
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
Ann. Onc.,
March 1, 2006;
17(3):
450 - 456.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Grothey and D. Sargent
Overall Survival of Patients With Advanced Colorectal Cancer Correlates With Availability of Fluorouracil, Irinotecan, and Oxaliplatin Regardless of Whether Doublet or Single-Agent Therapy Is Used First Line
J. Clin. Oncol.,
December 20, 2005;
23(36):
9441 - 9442.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Blanke
Whither Irinotecan?
J. Clin. Oncol.,
August 1, 2005;
23(22):
4811 - 4814.
[Full Text]
[PDF]
|
 |
|
|